SAB Biotherapeutics Inc（SABS）财务数据SABSSAB Biotherapeutics Inc

Evaluating the bottom line, SAB Biotherapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.21%, provide a clear picture of how effectively SABS converts its operational activities into shareholder value.

In the context of the broader market, SABS competes directly with industry leaders such as AGEN and DMAC. With a market capitalization of $336.65M, it holds a significant position in the sector. When comparing efficiency, SABS's gross margin of N/A stands against AGEN's 100.00% and DMAC's N/A. Such benchmarking helps identify whether SAB Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

SAB Biotherapeutics has shown a significant increase in its stock price over the past year, with a 78.77% increase. However, it has reported substantial net losses, including a net loss of $22.49 million in Q2 2026, and a forward P/E ratio of 0, indicating no earnings expected in the near term.